Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Allogene Therapeutics, Inc. (ALLO) had Free Cash Flow per Share of $-1.03 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.02M |
|
$-257.59M |
|
-- |
|
$0.02M |
|
$273.22M |
|
$-273.20M |
|
$16.05M |
|
$-257.15M |
|
$-257.15M |
|
$-257.59M |
|
$-257.59M |
|
$-257.59M |
|
$-257.59M |
|
$-273.20M |
|
$-267.91M |
|
194.81M |
|
194.81M |
|
$-1.32 |
|
$-1.32 |
|
| Balance Sheet Financials | |
$303.39M |
|
$86.06M |
|
$245.32M |
|
$548.71M |
|
$35.52M |
|
-- |
|
$91.01M |
|
$126.53M |
|
$422.18M |
|
$422.18M |
|
$422.18M |
|
212.21M |
|
| Cash Flow Statement Financials | |
$-200.30M |
|
$75.69M |
|
$116.67M |
|
$93.45M |
|
$85.51M |
|
$-7.94M |
|
$51.74M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1241814.00% |
|
-1241814.00% |
|
-1217764.00% |
|
-1168850.00% |
|
-1170864.00% |
|
$-200.99M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-61.01% |
|
-61.01% |
|
-46.94% |
|
-61.01% |
|
$1.99 |
|
|
Free Cash Flow per Share |
$-1.03 |
$-1.03 |
|